Summary
Thirty-four patients with acute myeloid leukemia (AML) in complete remission (CR), 30 of them aged over 60, received maintenance therapy scheduling four courses of low-dose cytarabine (LDA) 20 mg/m2/day in two subcutaneous injections for 3 weeks every 6 weeks. Each course was stopped when hematologic toxicity occurred, and doses of LDA were subsequently reduced by 50% for the following courses. During the first course of LDA, 15 patients needed blood and four patients platelet transfusions. Overall, 28 patients received four courses of LDA: 11 did not require any dose reduction, while 14 required one dose reduction and three neeeded two successive dose reductions. Two patients were hospitalized during maintenance. Median disease-free survival (DFS) is 308 days, with 16% of patients surviving at 5 years. Seven patients relapsed during the 168 days of maintenance, while ten of the 27 patients remaining at risk on day 169 relapsed during the 168 days following maintenance. We conclude that in AML in CR, the maximal dose of LDA tolerated by ambulatory patients is 10 mg/m2/day for 3 weeks. LDA seemed to delay relapse; however, precise assessment of the efficacy of this approach would require a randomized trial.
Similar content being viewed by others
References
Alessandrino EP, Orlandi E, Brusamolino E, Lazzarino M, Bernasconi C (1985) Low-dose ara-C in acute leukemia after a myelodysplastic syndrome and in elderly leukemia. Am J Hematol 20: 191–193
Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, Sultan C (1985) Proposed revised criteria for the classification of acute myeloid leukemia: a report of the French-American-British Cooperative Group. Ann Intern Med 103: 626–629
Bolwell BJ, Cassileth PA, Gale RP (1987) Low-dose cytosine arabinoside in myelodysplasia and acute myelogenous leukemia: a review. Leukemia 1: 575–579
Cheson BD, Jasperse DM, Simon R, Friedman MA (1986) A critical appraisal of low-dose cytosine arabinoside in patients with acute non-lymphocytic leukemia and myelodysplastic syndromes. J Clin Oncol 4: 1857–1864
Ellison RR, Holland JF, Weil M, Jacquillat C, Boiron M, Bernard J, Sawitsky A, Rosner F, Gussoff B, Silver RT, Karanas A, Cuttner J, Spurr CL, Hayes DM, Bloom J, Leone LA, Haurani F, Kyle R, Hutchinson JL, Forcier RJ, Moon JH (1968) Arabinosyl cytosine: a useful agent in the treatment of acute leukemia in adults. Blood 32: 507–523
Foon KA, Zighelboim J, Yale C, Gale RP (1981) Intensive chemotherapy is the treatment of choice for elderly patients with acute myelogenous leukemia. Blood 58: 467–470
Ho AD, Schwarz CE, Hunstein W (1985) Treatment of acute myeloid leukemia developing after a myelodysplastic phase with low-dose arabinosyl cytosine. Leuk Res 9: 1293–1298
Keating MJ, McKredie KB, Benjamin RS, Bodey GP, Zander A, Smith TL, Freireich EJ (1981) Treatment of patients over 50 years of age with acute myelogenous leukemia with a combination of rubidazone and cytosine arabinoside, vincristine and prednisone (ROAP). Blood 58: 584–591
Löwenberg B, Zittoun R, Kerkhofs H, Jehn U, Abels J, Debusscher L, Cauchie Ch, Peetermans M, Solbu G, Suciu S, Stryckmans P (1989) On the value of intensive remission-induction chemotherapy in elderly patients of 65 + years with acute myeloid leukemia: a randomized phase-III study of the European Organization for Research and Treatment of Cancer Leukemia Group. J Clin Oncol 7: 1268–1274
Pesce A, Cassuto JP, Bayle J, Raynoud S, Fuzibet JG, Gratecos N, Dujardin P (1986) Very-low-dose cytarabine for elderly patients. Lancet 1: 1436
Poirier O, Chomienne C, Castaigne S, Degos L, Abita JP, Najean Y (1986) Pharmacokinetic data on very-low-dose cytarabine. Lancet 1: 1436–1437
Powell BL, Capizzi RL, Muss HB, Bearden JD, Lyerly ES, Rosenbaum DL, Morgan TM, Richards F, Jackson DV, White DR, Nelson EC, Butler WM, Zekan PJ, Cruz JM, Cooper MR, Buss DH, Spurr CL (1989) Low-dose ara-C therapy for acute myelogenous leukemia in elderly patients. Leukemia 3: 23–28
Reiffers J, Reynal F, Braustet A (1980) Acute myeloblastic leukemia in elderly patients: treatment and prognostic factors. Cancer 45: 2816–2820
Sebban C, Archimbaud E, Coiffier B, Guyotat D, Treille-Ritouet D, Fiere D (1988) Treatment of acute myeloblastic leukemia in elderly patients. A retrospective study of 69 cases. Cancer 61: 227–231
Stein RS, Vogler WR, Winton EF, Cohen HJ, Raney MR, Bartolucci A (1990) Therapy of acute myelogenous leukemia in patients over the age of 50: a randomized Southeastern Oncology Group trial. Leuk Res 14: 895–903
Tilly H, Castaigne S, Bordessoule D, Casassus P, Le Prisé PY, Tertian G, Desablens B, Henry-Amar M, Degos L (1990) Lowdose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly. J Clin Oncol 8: 272–279
Worsley A, Mufti GJ, Copplestone JA, Oscier DG, Hamblin TJ (1986) Very-low-dose cytarabine for myelodysplastic syndrome and acute myeloid leukaemia in the elderly. Lancet 1: 966
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Archimbaud, E., Anglaret, B., Thomas, X. et al. Maintenance with low-dose cytarabine for acute myeloid leukemia in complete remission. Ann Hematol 65, 71–74 (1992). https://doi.org/10.1007/BF01698132
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01698132